Opus Genetics Extends Cash Runway to 2029 Amid Key Clinical Milestones
Event summary
- Opus Genetics reports $60M cash position as of Q1 2026, with $35M strategic financing from Oberland Capital Management expected to close by May 22, 2026.
- Company anticipates cash runway into 2029, supporting multiple clinical inflection points and potential product approvals.
- Upcoming data readout for Cohort 1 of OPGx-BEST1 gene therapy study expected in September 2026.
- LCA5 program accepted into FDA’s Rare Disease Evidence Principles (RDEP) program, with pivotal Phase 3 trial recruitment ongoing.
- RDH12, MERTK, and RHO programs expected to advance to clinical testing within the next 12 months.
The big picture
Opus Genetics is positioning itself for a series of critical clinical milestones, backed by a strong cash position and strategic financing. The company's focus on inherited retinal diseases (IRDs) aligns with the growing interest in gene therapies for rare diseases, where precision targeted approaches are reshaping treatment paradigms. The acceptance of LCA5 into the FDA’s RDEP program underscores the regulatory pathway's importance in accelerating approvals for rare disease therapies.
What we're watching
- Clinical Data Impact
- How the September 2026 data readout for OPGx-BEST1 will influence investor confidence and potential partnership opportunities.
- Regulatory Strategy
- Whether the acceptance of LCA5 into the FDA’s RDEP program will accelerate the pivotal Phase 3 trial and approval timeline.
- Execution Risk
- The pace at which Opus Genetics can advance its RDH12, MERTK, and RHO programs into clinical testing while managing its cash runway.
Related topics